Cannabigerovarin

Cannabigerovarin
Names
	IUPAC name 2-[(2E)-3,7-dimethylocta-2,6-dienyl]-5-propylbenzene-1,3-diol
	Other names Cannabigerovarol; CBGV
Identifiers
CAS Number	55824-11-8;
3D model (JSmol)	Interactive image;
ChemSpider	32702027;
PubChem CID	59444407;
UNII	34S78SNA69;
CompTox Dashboard (EPA)	DTXSID601345013 ;
	InChI InChI=1S/C19H28O2/c1-5-7-16-12-18(20)17(19(21)13-16)11-10-15(4)9-6-8-14(2)3/h8,10,12-13,20-21H,5-7,9,11H2,1-4H3/b15-10+;
	SMILES CCCC1=CC(=C(C(=C1)O)C/C=C(\C)/CCC=C(C)C)O;
Properties
Chemical formula	C19H28O2
Molar mass	288.431 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Cannabigerovarin (CBGV), the propyl homolog of cannabigerol (CBG), is a cannabinoid present in Cannabis.^[1]^[2]^[3]^[4] There is no observation related to the psychoactive or psychotropic effects of CBGV when consumed or inhaled.^[5]^[1] The possible benefits of cannabigerovarin in human bodies are painkilling and anti-inflammatory properties to treat conditions like fibromyalgia and arthritis, the treatment and improvement of the dry-skin syndrome, cancer treatment by reducing the growth of cancer cells in patients who have leukemia.^[6]^[5]^[7]^[8]^[9] According to the pain-relieving effects of this natural cannabinoid, it can be helpful to treat patients who were undergoing drug exposure like chemotherapy or radiation therapy.^[10]^[9] In addition, cannabigerol metabolism increases and has a better absorption from the body when paired with cannabigerovarin.^[11]

References

^ ^a ^b Tolomeo, Francesco; Russo, Fabiana; Vandelli, Maria Angela; Biagini, Giuseppe; Capriotti, Anna Laura; Laganà, Aldo; Carbone, Luigi; Gigli, Giuseppe; Cannazza, Giuseppe; Citti, Cinzia (September 2021). "HPLC–UV–HRMS analysis of cannabigerovarin and cannabigerobutol, the two impurities of cannabigerol extracted from hemp". Journal of Pharmaceutical and Biomedical Analysis. 203: 114215. doi:10.1016/j.jpba.2021.114215. ISSN 0731-7085. PMID 34153935.
^ "What is Cannabigerovarin (CBGV)?". Marijuana Doctors | Online Medical Card Directory. Retrieved 2021-11-24.
^ Hillig, Karl W.; Mahlberg, Paul G. (2004). "A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae)". American Journal of Botany. 91 (6): 966–975. doi:10.3732/ajb.91.6.966. ISSN 1537-2197. PMID 21653452. S2CID 32469533.
^ de Meijer, E. P. M.; Hammond, K. M.; Micheler, M. (2009-01-01). "The inheritance of chemical phenotype in Cannabis sativa L. (III): variation in cannabichromene proportion". Euphytica. 165 (2): 293–311. doi:10.1007/s10681-008-9787-1. ISSN 1573-5060. S2CID 24132168.
^ ^a ^b Oláh, Attila; Markovics, Arnold; Szabó-Papp, Judit; Szabó, Pálma Tímea; Stott, Colin; Zouboulis, Christos C.; Bíró, Tamás (September 2016). "Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment". Experimental Dermatology. 25 (9): 701–707. doi:10.1111/exd.13042. hdl:2437/243742. PMID 27094344. S2CID 39290296.
^ Chakravarti, Bandana; Ravi, Janani; Ganju, Ramesh K. (2014-07-17). "Cannabinoids as therapeutic agents in cancer: current status and future implications". Oncotarget. 5 (15): 5852–5872. doi:10.18632/oncotarget.2233. ISSN 1949-2553. PMC 4171598. PMID 25115386.
^ Burstein, Sumner (April 2015). "Cannabidiol (CBD) and its analogs: a review of their effects on inflammation". Bioorganic & Medicinal Chemistry. 23 (7): 1377–1385. doi:10.1016/j.bmc.2015.01.059. ISSN 0968-0896. PMID 25703248.
^ Grof, Christopher P. L. (2018-05-24). "Cannabis, from plant to pill". British Journal of Clinical Pharmacology. 84 (11): 2463–2467. doi:10.1111/bcp.13618. ISSN 0306-5251. PMC 6177712. PMID 29701252.
^ ^a ^b Alsen, Mathilda; Sinclair, Catherine; Cooke, Peter; Ziadkhanpour, Kimia; Genden, Eric; van Gerwen, Maaike (2021-01-19). "Endocrine Disrupting Chemicals and Thyroid Cancer: An Overview". Toxics. 9 (1): 14. doi:10.3390/toxics9010014. ISSN 2305-6304. PMC 7832870. PMID 33477829.
^ "What is CBGV?". Botany Farms. 2020-09-25. Retrieved 2021-11-24.
^ de Meijer, E. P. M.; Hammond, K. M. (September 2005). "The inheritance of chemical phenotype in Cannabis sativa L. (II): Cannabigerol predominant plants". Euphytica. 145 (1–2): 189–198. doi:10.1007/s10681-005-1164-8. ISSN 0014-2336. S2CID 13496446.

This cannabinoid related article is a stub. You can help Wikipedia by expanding it.

[:0-1] Tolomeo, Francesco; Russo, Fabiana; Vandelli, Maria Angela; Biagini, Giuseppe; Capriotti, Anna Laura; Laganà, Aldo; Carbone, Luigi; Gigli, Giuseppe; Cannazza, Giuseppe; Citti, Cinzia (September 2021). "HPLC–UV–HRMS analysis of cannabigerovarin and cannabigerobutol, the two impurities of cannabigerol extracted from hemp". Journal of Pharmaceutical and Biomedical Analysis. 203: 114215. doi:10.1016/j.jpba.2021.114215. ISSN 0731-7085. PMID 34153935.

[2] "What is Cannabigerovarin (CBGV)?". Marijuana Doctors | Online Medical Card Directory. Retrieved 2021-11-24.

[3] Hillig, Karl W.; Mahlberg, Paul G. (2004). "A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae)". American Journal of Botany. 91 (6): 966–975. doi:10.3732/ajb.91.6.966. ISSN 1537-2197. PMID 21653452. S2CID 32469533.

[4] Meijer, E. P. M.; Hammond, K. M.; Micheler, M. (2009-01-01). "The inheritance of chemical phenotype in Cannabis sativa L. (III): variation in cannabichromene proportion". Euphytica. 165 (2): 293–311. doi:10.1007/s10681-008-9787-1. ISSN 1573-5060. S2CID 24132168.

[:1-5] Oláh, Attila; Markovics, Arnold; Szabó-Papp, Judit; Szabó, Pálma Tímea; Stott, Colin; Zouboulis, Christos C.; Bíró, Tamás (September 2016). "Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment". Experimental Dermatology. 25 (9): 701–707. doi:10.1111/exd.13042. hdl:2437/243742. PMID 27094344. S2CID 39290296.

[6] Chakravarti, Bandana; Ravi, Janani; Ganju, Ramesh K. (2014-07-17). "Cannabinoids as therapeutic agents in cancer: current status and future implications". Oncotarget. 5 (15): 5852–5872. doi:10.18632/oncotarget.2233. ISSN 1949-2553. PMC 4171598. PMID 25115386.

[7] Burstein, Sumner (April 2015). "Cannabidiol (CBD) and its analogs: a review of their effects on inflammation". Bioorganic & Medicinal Chemistry. 23 (7): 1377–1385. doi:10.1016/j.bmc.2015.01.059. ISSN 0968-0896. PMID 25703248.

[8] Grof, Christopher P. L. (2018-05-24). "Cannabis, from plant to pill". British Journal of Clinical Pharmacology. 84 (11): 2463–2467. doi:10.1111/bcp.13618. ISSN 0306-5251. PMC 6177712. PMID 29701252.

[:2-9] Alsen, Mathilda; Sinclair, Catherine; Cooke, Peter; Ziadkhanpour, Kimia; Genden, Eric; van Gerwen, Maaike (2021-01-19). "Endocrine Disrupting Chemicals and Thyroid Cancer: An Overview". Toxics. 9 (1): 14. doi:10.3390/toxics9010014. ISSN 2305-6304. PMC 7832870. PMID 33477829.

[10] "What is CBGV?". Botany Farms. 2020-09-25. Retrieved 2021-11-24.

[11] Meijer, E. P. M.; Hammond, K. M. (September 2005). "The inheritance of chemical phenotype in Cannabis sativa L. (II): Cannabigerol predominant plants". Euphytica. 145 (1–2): 189–198. doi:10.1007/s10681-005-1164-8. ISSN 0014-2336. S2CID 13496446.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

Names


IUPAC name 2-[(2E)-3,7-dimethylocta-2,6-dienyl]-5-propylbenzene-1,3-diol
Other names Cannabigerovarol CBGV
Identifiers
CAS Number	55824-11-8
3D model (JSmol)	Interactive image
ChemSpider	32702027
PubChem CID	59444407
UNII	34S78SNA69
CompTox Dashboard (EPA)	DTXSID601345013
InChI InChI=1S/C19H28O2/c1-5-7-16-12-18(20)17(19(21)13-16)11-10-15(4)9-6-8-14(2)3/h8,10,12-13,20-21H,5-7,9,11H2,1-4H3/b15-10+
SMILES CCCC1=CC(=C(C(=C1)O)C/C=C(\C)/CCC=C(C)C)O
Properties
Chemical formula	C₁₉H₂₈O₂
Molar mass	288.431 g·mol⁻¹
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references